DRTS Logo

Alpha Tau Medical Ltd. (DRTS) Stock Forecast & Price Prediction

Live DRTS Stock Price & Analysis

Home โ€บ Stocks โ€บ Israel | NASDAQ | Healthcare | Biotechnology

$3.14

+0.08 (2.61%)

12 Month Price Forecast For DRTS

$3.14
Current Price
$220.47M
Market Cap
4 Ratings
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to DRTS Price Forecasts

+314.0%
To High Target of $13.00
+170.7%
To Median Target of $8.50
+59.2%
To Low Target of $5.00

DRTS Price Momentum

+0.6%
1 Week Change
-18.4%
1 Month Change
-2.2%
1 Year Change
+1.3%
Year-to-Date Change
-28.4%
From 52W High of $4.39
+79.4%
From 52W Low of $1.75

๐Ÿค” Considering Alpha Tau (DRTS)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 1:41 PM UTC

DRTS Analyst Ratings & Price Targets

Based on our analysis of 5 Wall Street analysts, DRTS has a bullish consensus with a median price target of $8.50 (ranging from $5.00 to $13.00). Currently trading at $3.14, the median forecast implies a 170.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

DRTS Analyst Consensus

4
Buy
0
Hold
0
Sell

DRTS Price Target Range

Low
$5.00
Average
$8.50
High
$13.00
Current: $3.14

Latest DRTS Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for DRTS.

Date Firm Analyst Rating Change Price Target
Nov 22, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Oct 23, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Oct 11, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Aug 20, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Aug 15, 2024 Piper Sandler Jason Bednar Overweight Reiterates $7.00
Jun 26, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
May 22, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
May 16, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Mar 12, 2024 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Mar 8, 2024 Piper Sandler Jason Bednar Overweight Reiterates $7.00
Dec 15, 2023 Citigroup Ashiq Mubarack Buy Initiates $8.00
Nov 20, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Nov 17, 2023 Piper Sandler Jason Bednar Overweight Maintains $8.00
Sep 20, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Aug 29, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
Aug 29, 2023 Cantor Fitzgerald Kristen Kluska Overweight Reiterates $23.00
Aug 18, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
May 24, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
May 18, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00
May 15, 2023 HC Wainwright & Co. Yi Chen Buy Reiterates $9.00

Stocks Similar to Alpha Tau Medical Ltd.

The following stocks are similar to Alpha Tau based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Alpha Tau Medical Ltd. (DRTS) Financial Data

Alpha Tau Medical Ltd. has a market capitalization of $220.47M with a P/E ratio of -7.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -37.2%.

Valuation Metrics

Market Cap $220.47M
Enterprise Value $160.54M
P/E Ratio -7.5x
PEG Ratio -6.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +29.8%
Current Ratio 11.0x
Debt/Equity 18.1x
ROE -37.2%
ROA -22.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Alpha Tau Medical Ltd. logo

Alpha Tau Medical Ltd. (DRTS) Company Overview

About Alpha Tau Medical Ltd.

What They Do

Develops innovative cancer radiation therapy.

Business Model

The company focuses on the research, development, and commercialization of its proprietary Alpha-DaRT technology. This therapy utilizes diffusing alpha-emitters for targeted radiation treatment of various solid tumors, generating revenue through clinical trial advancements and potential future product sales.

Additional Information

Alpha Tau Medical is currently in the clinical trial stage for multiple cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Founded in 2015 and headquartered in Jerusalem, Israel, the company is expanding its research to address additional cancers, indicating potential growth in both treatment options and market reach.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

121

CEO

Mr. Uzi Sofer

Country

Israel

IPO Year

2021

Alpha Tau Medical Ltd. (DRTS) Latest News & Analysis

DRTS stock latest news image
Quick Summary

Alpha DaRTยฎ shows high disease control rates and strong interim safety results in pancreatic cancer patients across three trials.

Why It Matters

Promising trial results for Alpha DaRT in pancreatic cancer could indicate a potential breakthrough treatment, influencing stock valuations and future investment in biotech firms involved.

Source: GlobeNewsWire
Market Sentiment: Neutral
DRTS stock latest news image
Quick Summary

Alpha Tau Medical Ltd. announced the appointment of Ms. Maya Netser to its Board of Directors, replacing Mr. Meir Jakobsohn, who will serve in an advisory role after his term ends.

Why It Matters

Board changes can signal strategic shifts or new directions for a company. Maya Netser's appointment may influence Alpha Tau's future strategies, impacting investor sentiment and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
DRTS stock latest news image
Quick Summary

Alpha Tau Medical's study on its alpha-radiation therapy for pancreatic cancer will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium on January 24, 2025.

Why It Matters

The acceptance of Alpha Tau's trial results for presentation at a major oncology symposium highlights credibility and potential market interest, which could influence stock performance and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
DRTS stock latest news image
Quick Summary

The company's upcoming presentation will highlight recent achievements and provide insights on future data milestones.

Why It Matters

The presentation highlights the company's recent successes and future data milestones, which can impact stock performance and investor sentiment. Positive achievements may boost confidence and valuations.

Source: GlobeNewsWire
Market Sentiment: Neutral
DRTS stock latest news image
Quick Summary

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium on December 6, 2024.

Why It Matters

CFO Raphi Levy's presentation at a key oncology symposium could enhance Alpha Tau's visibility, attract investor interest, and potentially impact stock performance due to new insights or partnerships.

Source: GlobeNewsWire
Market Sentiment: Neutral
DRTS stock latest news image
Quick Summary

Alpha Tau Medical's CFO Raphi Levy will speak at the Citi Global Healthcare Conference on December 3, 2024, and the Piper Sandler Healthcare Conference on December 5, 2024.

Why It Matters

CFO participation in major healthcare conferences can signal potential growth and investment interest, indicating Alpha Tau's strategic positioning in the cancer therapy market.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About DRTS Stock

What is Alpha Tau Medical Ltd.'s (DRTS) stock forecast for 2025?

Based on our analysis of 5 Wall Street analysts, Alpha Tau Medical Ltd. (DRTS) has a median price target of $8.50. The highest price target is $13.00 and the lowest is $5.00.

Is DRTS stock a good investment in 2025?

According to current analyst ratings, DRTS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.14. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for DRTS stock?

Wall Street analysts predict DRTS stock could reach $8.50 in the next 12 months. This represents a 170.7% increase from the current price of $3.14. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Alpha Tau Medical Ltd.'s business model?

The company focuses on the research, development, and commercialization of its proprietary Alpha-DaRT technology. This therapy utilizes diffusing alpha-emitters for targeted radiation treatment of various solid tumors, generating revenue through clinical trial advancements and potential future product sales.

What is the highest forecasted price for DRTS Alpha Tau Medical Ltd.?

The highest price target for DRTS is $13.00 from at , which represents a 314.0% increase from the current price of $3.14.

What is the lowest forecasted price for DRTS Alpha Tau Medical Ltd.?

The lowest price target for DRTS is $5.00 from at , which represents a 59.2% increase from the current price of $3.14.

What is the overall DRTS consensus from analysts for Alpha Tau Medical Ltd.?

The overall analyst consensus for DRTS is bullish. Out of 5 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.50.

How accurate are DRTS stock price projections?

Stock price projections, including those for Alpha Tau Medical Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.